ORPHA:3148
Malignant peripheral nerve sheath tumor
Also known as: MPNST · Malignant neurilemmoma · Malignant neurofibroma · Malignant schwannoma · Neurofibrosarcoma · Neurogenic sarcoma
Publications
15,603
Trials
41
Interventional, condition-specific
Researchers
1,217
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
Malignant peripheral nerve sheath tumor (MPNST) is a rare and often aggressive soft tissue sarcoma occurring in a wide range of anatomical sites.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017827
- UMLS:C0751690
- NCIT:C3798
Additional Mondo synonyms (19)
Malig. periph. nerve sheath tum. · malignant neoplasm of peripheral nerve sheath · malignant neurilemmoma · malignant neurilemoma · malignant neurofibroma · malignant peripheral nerve sheath neoplasm · malignant peripheral nerve sheath tumor · malignant peripheral nerve sheath tumor (morphologic abnormality) · malignant peripheral nerve sheath tumor [dup] (morphologic abnormality) · malignant peripheral nerve sheath tumour (morphologic abnormality) · malignant peripheral nerve sheath tumour [dup] (morphologic abnormality) · malignant schwannoma · malignant tumor of peripheral nerve sheath · malignant tumor of the peripheral nerve sheath · malignant tumour of peripheral nerve sheath · malignant tumour of the peripheral nerve sheath · neurofibrosarcoma, malignant · neurogenic sarcoma · schwannoma, malignant
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
15,603 matched papers (8,544 in last 10 years) Source
- Phenotype characterisedPresent
1 HPO annotations (e.g. Adult onset) Source
- Animal modelPresent
7 genotype models (Danio rerio, Rattus norvegicus, Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
41 matched on ClinicalTrials.gov (11 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Animal models (Monarch / Alliance)
7
Model associations linked to this Mondo ID
- tp53zdf1/zdf1·ZFIN:ZDB-FISH-150901-16688·Danio rerio
- BDIX/Ifz·RGD:2307318·Rattus norvegicus
- BDIV/lfz·RGD:737921·Rattus norvegicus
- BDIX.BDIV-D6Mit1-D6Mgh2/Zte·RGD:12738372·Rattus norvegicus
- Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Cnp-EGFR)10Nrat/0 Tg(Dhh-cre)1Mejr/0 [background:] involves: 129S1/Sv * C57BL/6 * FVB/N * SJL·MGI:5485414·Mus musculus
- Cdkn2atm1Rdp/Cdkn2atm1Rdp Nf1tm1Tyj/Nf1+ [background:] involves: 129S2/SvPas * 129S6/SvEvTac·MGI:3776069·Mus musculus
- Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Gfap-cre)77.6Mvs/0 [background:] involves: 129S4/SvJae * BALB/c * C57BL/6NHsd·MGI:4849441·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
39
Drugs / clinical candidates · MONDO_0017827
- DACARBAZINE·phase 3
- DOCETAXEL·phase 3
- EPIRUBICIN·phase 3
- ETOPOSIDE·phase 3
- GEMCITABINE·phase 3
- IFOSFAMIDE·phase 3
- TRABECTEDIN·phase 3
- ALISERTIB·phase 2
- BEVACIZUMAB·phase 2
- CEDAZURIDINE·phase 2
- CISPLATIN·phase 2
- DECITABINE·phase 2
- DOXORUBICIN HYDROCHLORIDE·phase 2
- DURVALUMAB·phase 2
- ERLOTINIB HYDROCHLORIDE·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
15,603
15,603 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
15,603 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
8,544 in the last 10 years · low confidence
Phrase hits: 15,603 · MeSH hits: 0
Who's working on it?
1,217
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Spinner RJ6 papers · 2026
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Papers in Europe PMC - 02Wang H6 papers · 2026
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Papers in Europe PMC - 03Gel B4 papers · 2026
Hereditary Cancer Group, CARE Translational Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Papers in Europe PMC - 04Hirbe AC4 papers · 2026
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. hirbea@wustl.edu.
Papers in Europe PMC - 05Serra E4 papers · 2026
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Papers in Europe PMC - 06Zhang Y4 papers · 2026
Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Henan, China.
Papers in Europe PMC - 07Antonescu CR3 papers · 2026
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Papers in Europe PMC - 08Carrió M3 papers · 2026
Hereditary Cancer Group, CARE Translational Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Papers in Europe PMC - 09Chen L3 papers · 2026
Department of Sports Medicine, Rizhao People's Hospital, Rizhao, Shandong, China.
Papers in Europe PMC - 10Chrabąszcz K3 papers · 2026
Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 Krakow, Poland. karolina.chrabaszcz@ifj.edu.pl.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
41
interventional trials for this specific condition
41 interventional trials matched this specific condition name; 11 currently recruiting in our sample.
Data as of 11 September 2026
41 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.8th percentile).
low confidence · 96.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
41 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT04222413·RECRUITING·Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Not reviewed·Conditions: Advanced Solid Tumors · Metastatic Pancreatic Cancer · Pediatric Solid Tumor · Advanced Breast Cancer·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Not reviewed·Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT05985161·RECRUITING·A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Not reviewed·Conditions: Wilms Tumor · Rhabdoid Tumor · Malignant Peripheral Nerve Sheath Tumors · MPNST·Matched via name phrase
- NCT06693284·RECRUITING·A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
Not reviewed·Conditions: Primary Malignant Peripheral Nerve Sheath Tumors·Matched via name phrase
- NCT06735820·RECRUITING·Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Not reviewed·Conditions: Malignant Peripheral Nerve Sheath Tumor (MPNST) · Neurofibromatosis 1 (NF1) · Atypical Neurofibroma·Matched via name phrase
- NCT05253131·NOT YET RECRUITING·Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Not reviewed·Conditions: MPNST · NF1 · Sarcoma·Matched via name phrase
- NCT04872543·RECRUITING·A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Not reviewed·Conditions: Malignant Peripheral Nerve Sheath Tumors (MPNST)·Matched via name phrase
- NCT06526897·NOT YET RECRUITING·Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
Not reviewed·Conditions: Adult Pleomorphic Rhabdomyosarcoma · AJCC Grade 2 Sarcoma · AJCC Grade 3 Sarcoma · Alveolar Soft Part Sarcoma·Matched via name phrase
- NCT07549022·NOT YET RECRUITING·Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
Not reviewed·Conditions: Malignant Peripheral Nerve Sheath Tumors · MPNST·Matched via name phrase
- NCT05642455·RECRUITING·SPEARHEAD-3 Pediatric Study
Not reviewed·Conditions: Synovial Sarcoma · Malignant Peripheral Nerve Sheath Tumor (MPNST) · Neuroblastoma (NBL) · Osteosarcoma·Matched via name phrase
- NCT06849986·RECRUITING·IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Not reviewed·Conditions: Soft Tissue Sarcomas · Angiosarcoma · Fibrosarcoma · Leiomyosarcoma·Matched via name phrase
Observational and natural-history studies
6 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07298083·RECRUITING·DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Not reviewed·Conditions: Neurofibromas · MPNST·Matched via name phrase
- NCT06515860·RECRUITING·Neurofibromatosis Type 1 Tumor Early Detection Study
Not reviewed·Conditions: Neurofibromatosis Type 1 · Neurofibromatosis 1 · Plexiform Neurofibroma · Plexiform Neurofibromas·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (4)
- ctis·2024-520318-23-00·Authorised·Phase I/II randomized clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas
skipped — LLM skipped (--skip-llm)
- ctis·2023-510553-41-00·Cancelled·TAZEMETOSTAT ROLLOVER STUDY (TRUST): AN OPEN-LABEL, ROLLOVER STUDY
skipped — LLM skipped (--skip-llm)
- ctis·2024-510877-67-00·Cancelled·Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas
skipped — LLM skipped (--skip-llm)
- ctis·2024-510712-75-00·Authorised, ongoing·COTESARC : A multicentre, open-label, Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Malignant peripheral nerve sheath tumor — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Malignant peripheral nerve sheath tumor" OR "MPNST" OR "Malignant neurilemmoma" OR "Malignant neurofibroma" OR "Malignant schwannoma" OR "Neurofibrosarcoma" OR "Neurogenic sarcoma" OR "Malig. periph. nerve sheath tum." OR "malignant neoplasm of peripheral nerve sheath" OR "malignant neoplasm of the peripheral nerve sheath" OR "malignant neurilemoma" OR "malignant peripheral nerve sheath neoplasm" OR "malignant peripheral nerve sheath tumor (morphologic abnormality)" OR "malignant peripheral nerve sheath tumor [dup] (morphologic abnormality)" OR "malignant peripheral nerve sheath tumour (morphologic abnormality)" OR "malignant peripheral nerve sheath tumour [dup] (morphologic abnormality)" OR "malignant tumor of peripheral nerve sheath" OR "malignant tumor of the peripheral nerve sheath" OR "malignant tumour of peripheral nerve sheath" OR "malignant tumour of the peripheral nerve sheath" OR "neurofibrosarcoma, malignant" OR "schwannoma, malignant"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Malignant peripheral nerve sheath tumor" OR "MPNST" OR "Malignant neurilemmoma" OR "Malignant neurofibroma" OR "Malignant schwannoma" OR "Neurofibrosarcoma" OR "Neurogenic sarcoma" OR "Malig. periph. nerve sheath tum." OR "malignant neoplasm of peripheral nerve sheath" OR "malignant neoplasm of the peripheral nerve sheath" OR "malignant neurilemoma" OR "malignant peripheral nerve sheath neoplasm" OR "malignant peripheral nerve sheath tumor (morphologic abnormality)" OR "malignant peripheral nerve sheath tumor [dup] (morphologic abnormality)" OR "malignant peripheral nerve sheath tumour (morphologic abnormality)" OR "malignant peripheral nerve sheath tumour [dup] (morphologic abnormality)" OR "malignant tumor of peripheral nerve sheath" OR "malignant tumor of the peripheral nerve sheath" OR "malignant tumour of peripheral nerve sheath" OR "malignant tumour of the peripheral nerve sheath" OR "neurofibrosarcoma, malignant" OR "schwannoma, malignant"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 41 interventional · 6 observational · 2 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (15603) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T22:19:28.022Z
